Interim report

January 1 – June 30, 2018

The second quarter in figures

- Net sales amounted to TSEK 1,571 (2,046).
- The loss after tax amounted to TSEK 10,298 (11,746).
- The loss per share amounted to SEK 0.62 (1.42).
- The cash flow from current operations was negative in the amount of TSEK 10,119 (11,044).
- The gross margin was 58.2% (34.2%).
- Electrode sales in volume decreased by 18% and reached 4,304 (5,232) units. Repeat sales of electrodes decreased by 7%.

The first half-year in figures

- Net sales amounted to TSEK 3,510 (3,801).
- The loss after tax amounted to TSEK 19,955 (23,358).
- The loss per share amounted to SEK 1.20 (2.82).
- The cash flow from current operations was negative in the amount of TSEK 19,801 (23,025).
- The gross margin was 51.7% (30.6%).
- Electrode sales in volume decreased by 10% and reached 8,438 (9,328) units. Repeat sales of electrodes increased by 5%.

Important events during the quarter

- In the period SciBase presented major improvements to Nevisense. The key improvement is the elimination of the need for a reference measurement, which up until now has been the most complex part of the Nevisense test. Removing this streamlines the measurement procedure and makes Nevisense straightforward to learn and use. This is a very important improvement in usability and makes the product much easier to integrate into the patient flow at dermatology clinics.
- The AGM 2018 was held on May 16th, 2018
- The first Nevisense article by US researchers was published by Svoboda, Rigel et al. in SKIN, The journal of cutaneous medicine

Important events after the end of the period

- The FOBI meeting in Munich in July was the first meeting where the improved Nevisense was presented. Prof Axel Hauschild presented Nevisense in a workshop with nearly 100 attendees.

Financial overview

	Apr 1 - June 30		Jan 1 - June 30		July 1 2017 - June 30 2018	Jan 1 - Dec 31
THE GROUP	2018	2017	2018	2017	Rolling-12	2017
Net sales, SEK ths	1 571	2 046	3 510	3 801	6 568	6 859
Gross margin, %	58,2%	34,2%	51,7%	30,6%	46,8%	35,4%
Equity/Asset ratio, %	92,0%	87,2%	92,0%	87,2%	89,9%	90,5%
Net indebtness, multiple	0,09	0,15	0,09	0,15	0,11	0,11
Cash equivalents, SEK ths	85 231	60 974	85 231	60 974	85 231	110 015
Cashflow from operating activities, SEK ths	-10 119	-11 044	-19 801	-23 025	-40 955	-44 180
Earnings per share (before and after dilution), SEK	-0,62	-1,42	-1,20	-2,82	-3,09	-5,00
Shareholder's equity per share, SEK	5,76	8,38	5,76	8,38	7,80	13,63
Average number of shares, 000'	16 618	8 285	16 618	8 285	10 576	8 493
Number of shares at closing of period, 000'	16 618	8 285	16 618	8 285	16 618	16 618
Share price at end of period, SEK	6,45	19,08	7,45	19,08	7,45	7,80
Number of sold electrodes, pieces	4 304	5 232	8 438	9 328	15 814	16 704
Average number of employees	20	21	20	22	20	21

Definitions and a glossary are provided on page 17.

Comment by CEO Simon Grant

" Difficult sales quarter, major product improvement milestone"

Q2 Highlights

- Major method and product improvement (Nevisense 3.0) was released to the first 25 clinics in Germany. The release both simplifies testing significantly and also improves clinical accuracy.
- Nevisense 3.0 was presented for the first time at a highly successful FOBI meeting in Munich late July.
- Sales in the quarter were disappointing, partly driven by a 'wait and see' attitude to the new system.
- Improved gross margin reaching 58.2 % (34.2 %)
- Operating expenses decreased in the quarter by 12 % (excluding currency effects) resulting in a loss decreased by MSEK 1.4 for the quarter.
- In the US, focus remains on reimbursement activities with the first insurance claim estimated to be submitted by a US customer in August.

Major Nevisense improvement released

As we previously discussed, it has been an ongoing goal to simplify the Nevisense method and to better integrate Nevisense into the clinic's patient flow. In this respect the second quarter was a breakthrough quarter for the Nevisense method and a very important milestone for SciBase.

Nevisense 3.0 is a major algorithm and method update based on the new hardware and software platforms launched last year. After 9 months of development, testing and validation we were pleased to announce the release of an improved version of the Nevisense method and software, Nevisense 3.0. This is the most significant update of Nevisense to date and it was released to 25 users in Germany for clinical feedback before the general market release in Q3.

The release includes the following improvements and benefits for customers:

- The removal of the need for a separate reference measurement reduces the number of steps and dramatically simplifies the measurement time procedure.
- Elimination of almost all 'reference issues and thus standardising the measurement time.
- Improved accuracy with pivotal trial sensitivity increasing to 97% and specificity to 38%
- Measurement procedure is easier for operators to learn and use.
- It is easier to integrate Nevisense into the clinic workflow which should improve usage.

Feedback from the first 25 customers has been overwhelmingly positive and from the first clinics we have analysed in detail, we see an improvement in usage rates. We expect that this will significantly improve the uptake of Nevisense in Germany and elsewhere. In time we also hope to upgrade all existing customers to the new version.

Sales

The Q2 sales results were disappointing and reflected the challenge we face to get Nevisense included and used regularly in standard clinical practice. It also reflects a 'wait and see' attitude when it comes to the new Nevisense version. Though we have released the system to the first 25 clinics, we don't expect to start full sales efforts until the end of August when clinics return from the holiday break.

The FOBI meeting held in Munich at the end of July was the first time Nevisense 3.0 was presented at a congress. This included a very successful workshop from Prof Axel Hauschild which attracted nearly 100 attendees. Overall the response to the new version was extremely positive and included more than 20 customers who have requested upgrades to the new system.

Prof Hauschild workshop and SciBase exhibition

USA

Our focus in Q2 in the US has been on reimbursement and getting billing going with our first customers. We hope that three users will start issuing insurance claims in the coming weeks. This is the first step to discussions with insurance companies. Parallel to this we work to gather US clinical data to support our case for broad reimbursement.

We continue to work to acquire new customers and we also hope to see more published data from US physicians in the coming 3-6 months.

We also continue our work with the FDA to release the improvements available in Europe in the US. This is an ongoing process. The estimated time to receive US approval for Nevisense 3.0 is today not clear as it depends on the requirements set by the FDA.

A very interesting clinical trial has been published in JAMA Dermatology in the US showing that PA's (Physicians Assistants), who handle many patients, not only have a higher rate of biopsies/excisions than dermatologists but also appear to detect fewer melanomas. This is very interesting and fuels the discussion as to how Nevisense can add value in the US environment.

Margins

We were very pleased with the improvement in gross margin that we saw in Q2 where we reached 58.2% for the quarter compared to 34.2% for Q2 last year. Our long-term goal for gross margin is 70% and though the quarterly margin will fluctuate, we are making good progress towards this target. The good result in Q2 was partly to do with product mix and currency effects but overall the improvements delivered by the manufacturing team have been outstanding. As discussed in the Q1 report, the robot 'Emilia' used for electrode production has contributed to an improved production capacity, yield, an improved work environment and a lower production cost.

Continued cost focus and improved EBIT

Although improvements to Nevisense and the US market have been the main focus areas for the company during the first half of 2018, we have also been successful in controlling costs. With the finalization of the PMA, FDA costs have been lowered and we have utilized primarily internal resources for product development. Our operating expenses decreased by 12% y-o-y and by 13% if cleared for negative currency effects. This helped drive an improvement in EBIT.

We continue to focus our activities in accordance with the strategy we presented in the fall of 2017. The capital raised in December has given us a relatively strong cash position, but we are fully aware that our key challenge is to drive sales. Our focus is clearly on securing new Nevisense customers and on improving electrode usage rates at the customers we already have. We are encouraged by the initial reactions to Nevisense 3.0 and believe this will drive the needed sales development in Q3 to some extent, but especially in Q4.

Simon Grant, CEO
Sundbyberg August 21, 2018



SciBase in brief

About SciBase

SciBase is a medical technology company that develops instruments for detection of skin cancer and other skin conditions. The Nevisense product can detect malignant melanoma, the most dangerous form of skin cancer, directly on the skin without needing to cut away suspected moles. The product is based on comprehensive research on Electrical Impedance Spectroscopy (EIS), and SciBase has conducted the largest study to date on the detection of malignant melanoma, in which Nevisense achieved excellent results. The study was published in May 2014 in the prestigious British Journal of Dermatology. Nevisense is approved for sale in the United States (PMA), Europe (CE mark) and Australia.

In addition to detecting malignant melanoma, SciBase plans to increase the number of clinical applications for Nevisense. By using Nevisense as a platform, the Company may integrate functionality that uses the EIS method in assessing other skin diseases, such as non-melanoma skin cancer and atopic dermatitis. During 2017, SciBase launched a new type of electrode as well as new software and functionality for this purpose. Currently SciBase is conducting clinical trials with leading academic and clinical centers. The plan is to start commercialization of the first application in 2018.

SciBase was founded in 1998 by Stig Ollmar, a researcher at The Karolinska Institute, and has its headquarters in Stockholm. The company is listed on the Nasdaq First North exchange since June 2, 2015 and Avanza is the Company's certified advisor.

Business model

The company's business model is based on customers initially purchasing a Nevisense instrument then buying disposables (electrodes) on an on-going basis. Each electrode can only be used on one patient but on multiple moles or skin areas.

Short facts

- Skin cancer is the most common and fastest-growing form of cancer in the world.
- Malignant melanoma is the most dangerous form of skin cancer with a high mortality rate if not detected early.
- In the United States, expenditure for the treatment of malignant melanoma is approximately USD 3.3 billion annually, equivalent to 41% of expenditure for skin cancer. In recent years, expenditure has increased four-fold.
- Today, some 50-60 million annual examinations for malignant melanoma are performed, of which 5-6 million lead to excisions. Of these, some 86-97% are shown to be benign.
- With SciBase's Nevisense® the number of unnecessary interventions can be reduced by up to 50%, representing a reduction of up to 2.4 million interventions annually and thus leading to significant cost savings.
- Nevisense® provides physicians with an objective instrument to support better diagnoses.
- Management of atopic dermatitis (eczema) represents the greatest burden globally of all skin diseases. As many as 20 percent of all children and between 1 and 10 percent of all adults are afflicted by atopic dermatitis.
- The number of patients affected by non-melanoma skin cancer (NMSC) is over ten times the number affected by melanoma. In the US there are approximately 2.8M cases of basal cell carcinoma (a common type of NMSC) each year.

About Nevisense 3.0

'With the new and uncomplicated measurement method I feel more secure and enjoy using Nevisense on patients,*" Diana Siebert, MTA, Praxis Dr Hundgeburth, Cologne, Germany*

US facts

- There are expected be 91,000 cases of invasive melanoma and 87,000 cases of in situ melanoma in the US in 2018
- There are more cases of skin cancer than all other cancers combined – though only 3% of these cases are melanoma
- Melanoma is the fifth most common cancer among men and the sixth most common for women
- The lifetime risk for melanoma in the US is 1 in 24









Second quarter

Net Sales

Net sales for the second quarter of 2018 amounted to TSEK 1,571 (2,046), an decrease of 23%, cleared for currency effects the sales decreased by 29%. Of this, sales of instruments accounted for TSEK 107 (438) and sales of electrodes for TSEK 1,463 (1,610). In the period the company presented that a new and much improved version of Nevisense will be launched. This has affected the sales, especially of devices, negatively. When the updated version was presented at the FOBI-meeting (at the end of July) it met with a lot of interest and many customers expressed an interest to receive a demonstration and try it in their own clinic. The sales in Germany, where we have our primary focus, accounted for 100 (91)% of the sales in the period. Sales in Germany decreased by 16% compared to the second quarter of 2017. Cleared for currency effects the sales in Germany decreased by 21%.

The total sales of electrodes in the quarter reached 4,304 (5,232), a decrease of 18%. In Germany the total sales of electrodes in volume decreased by 12% while repeat sales decreased by 7%.

Operating profit/loss

The operating loss for the period April - June 2018 amounted to TSEK 10,239 (11,718), a decreased loss of TSEK 1,479. The improved operating result is mainly due to decreased development expenses as a result of most of the product development in 2018 being done by internal resources in comparison to the corresponding period of 2017 when a number of projects were utilizing external consultants and an improved gross margin. In spite of increased market investments and negative currency effects the operating expenses decreased by 10%, cleared for currency effects the decrease was 12%.

The gross margin in the period was 58.2 (34.2)%. The main reasons for the improved margin level were a stable production with an improved yield through the introduction of a semi-automated process and positive currency effects. When cleared for currency effects the gross margin would have been 55%. The margin is very volume dependent.

Sales and marketing expenses decreased by TSEK 257 and amounted to TSEK 5,765 (6,022). The expenses has in the period been affected by continued increased market investments in the US and negative currency effects balanced in-part by decreased headcount and marketing expenses outside Germany and the US.

Administration expenses for the period amounted to TSEK 2,502 (2,378), an increase of TSEK 124. The increase is mainly due to new patent applications.

Development expenses for the period amounted to TSEK 2,903 (3,979), a decrease of TSEK 1,076. The decrease is primarily thanks to reduced consultancy expenses and during the first half of 2017 finalized development projects.

Cash flow, investments and financial position

At the beginning of the period, cash and cash equivalents amounted to TSEK 95,542 and, at the end of the period, to TSEK 85,232.

Cash flow from current operations for the period was negative to the amount of TSEK 10,119 (11,044), of which changes in working capital amounted to a negative TSEK 189 (positive 477). The negative operating cash flow improved mainly due to the reduced loss. Total cash flow for the period was negative to the amount of TSEK 10,265 (negative 11,672).

Net investments in tangible assets for the period amounted to TSEK 146 (628) and mainly involved investments in demo instruments. Investments in intangible assets for the period amounted to TSEK 0 (0).

Depreciation of tangible assets was charged against earnings for the period to the value of TSEK 201 (191).

First half-year

Net Sales

Net sales for the second quarter of 2018 amounted to TSEK 3,510 (3,801), a decrease of 8%, cleared for currency effects the sales decreased by 14%. Of this, sales of instruments accounted for TSEK 706 (967) and sales of electrodes for TSEK 2,804 (2,834). The sales in Germany, where we have our primary focus, accounted for 98 (92)% of the sales in the period. Sales in Germany decreased in value by 2% compared to the first half of 2017. Cleared for currency effects the sales in Germany decreased by 7%.

The total sales of electrodes in the first half-year reached 8,438 (9,328), a decrease of 10%. In Germany the total sales of electrodes in volume decreased by 3% while repeat sales increased by 5%.

Operating profit/loss

The operating loss for the period January - June 2018 amounted to TSEK 19,829 (23,329), a decreased loss of TSEK 3,500. The improved operating result is mainly due to decreased development expenses for the in the second quarter 2017 completed PMA process and decreased external consultants, reduced administration expenses and an improved gross margin. In spite of increased market investments and negative currency effects the operating expenses decreased by 12%, cleared for currency effects the decrease was 13%.

The gross margin in the period was 51.7 (30.6)%. The main reasons for the improved margin level were a stable production with an improved yield through the introduction of a semi-automated process, positive currency effects and that the margin in Q1 2017 was negatively affected by scrapping. Cleared for currency effects the gross margin would have been 48%. The margin is very volume dependent.

Sales and marketing expenses increased by TSEK 191 and amounted to TSEK 11,714 (11,523). The expenses increased mainly due to increased market investments in the US and negative currency effects in-part balanced by reduced headcount and activities outside Germany and the US.

Administration expenses for the period amounted to TSEK 4,646 (4,848), a decrease of TSEK 202. The decrease is mainly thanks to reduced consultancy costs and lower rent for the offices. The administration expenses in 2017 included relocation expenses of the Company's head offices.

Development expenses for the period amounted to TSEK 5,279 (8,046), a decrease of TSEK 2,767. The decreased expenses are primarily due to a MSEK 1.3 (0.2 vs 1.5) decrease in the period due to the in Q2 2017 completed PMA process and reduced external consultants.

Cash flow, investments and financial position

At the beginning of the period, cash and cash equivalents amounted to TSEK 110,015 and, at the end of the period, to TSEK 85,232.

Cash flow from current operations for the period was negative to the amount of TSEK 19,801 (23,025), of which changes in working capital amounted to a negative TSEK 525 (negative 81). The negative operating cash flow improved mainly due to the reduced loss. Total cash flow for the period was negative to the amount of TSEK 24,721 (negative 23,998). The total cash flow was negatively affected by during the first quarter paid issue costs of MSEK 4.7 related to the in December 2017 closed new share issue.

Net investments in tangible assets for the period amounted to TSEK 251 (973) and mainly involved investments in demo instruments. Investments in intangible assets for the period amounted to TSEK 0 (0).

Depreciation of tangible assets was charged against earnings for the period to the value of TSEK 407 (349).

Other disclosures

Shareholders

At the end of the period, SciBase Holding AB had approximately 1,187 shareholders, of whom the three largest represented approximately 37.4% of the capital and votes. The total number of shares amounts to 16,618,101. The largest shareholders as of June 30, 2018 were SEB Venture Capital (13%), SEB Pensionsstiftelse (13%) and Fouriertransform AB (12%).

At an extraordinary shareholders meeting held on April 28, 2015 it was resolved to implement an incentive program. The program comprises a maximum of 553,863 warrants of which 392,317 have been allotted so far. For a full description of the program please see the Company's website and the minutes from the EGM on April 28th 2015.

Market overview

Skin cancer is believed to be the most common form of cancer in the world. More than 3.5 million cases of skin cancer are reported every year in the US alone, which is more than all other cancers combined. Currently around 50 million formal skin cancer screenings are estimated to be performed annually in SciBase's target geographies. The cost for these 50 million screenings is estimated to be around USD 2 billion. Around 10-15% of patients exhibit lesions that are atypical and can be difficult to judge. Though there is considerable variation, approximately 10% or 5 million lesions are suspicious enough to be excised. These 5 million annual excisions represent SciBase's initial target market where Nevisense could help to improve the quality of the diagnosis.

Of the five million estimated annual excisions performed in SciBase's target markets around 95% or 4.8 million lesions are later found to be benign. Uncertainty in the detection of malignant melanoma due to inexperience and limitations of visual screening methods leads physicians to excise many lesions 'just in case', as physicians do not want to risk missing a melanoma. The excision and biopsy of benign (harmless, i.e. not skin cancers) lesions due to uncertainty of visual screening methods is estimated to cost payers around USD 1.5 billion annually. SciBase estimates that Nevisense could reduce the number of benign lesion excisions by 34-50% (1.6-2.4 million lesions annually) based on the EIS score. These lesions represent around MUSD 520-770 in excision costs that can be avoided with SciBase method.

Employees

At the end of the year, the number of employees amounted to 20 (23), of whom 40 (30)% were women. This includes the production employees at our Uppsala electrode production facility and salespeople in Germany.

Financing

The Board of Directors regularly reviews the company's existing and forecast cash flows to ensure that the company has the funds and resources necessary to pursue operations and strategic focus adopted by the Board. The company's long-term cash needs are largely determined by how successful the current product will be/is in the market, developments and regulatory events that could affect the company's ability to sell its products or that would affect compensation levels in insurance systems for the use of the company's products as well as the expenditure associated with these efforts.

In December of 2017 the Company performed a rights issue that, before issue costs, provided the Company with SEK 75 million. The net contribution was approximately SEK 66 million. It is the Board's opinion that the current financial assets is sufficient to realize the Company's current business plan.

Transactions with related parties

In the period, the parent Company SciBase Holding AB has invoiced TSEK 2,153 (2,153) to the fully owned subsidiary SciBase AB, which corresponds to a 100% of the parent Company's turnover in the period. During the reporting period there were no other transactions with related parties that had any material impact on the Group or Parent Company's position and earnings.

Risks and uncertainty

The principal risks and sources of uncertainty for SciBase include, albeit not exclusively, financial risks, such as the future earnings trend, financing, and currency and credit risks. In addition to market risks, there are also risks associated with SciBase's operations, such as obtaining necessary approval from authorities, product development, patents and intellectual property rights, product responsibility and forward looking info. Nor are there any guarantees that the Company will be able to secure the financial resources necessary to conduct its operations. Further information on the Company's risk exposure can be found on pages 34-37 of SciBase's 2017 Annual Report.

Parent Company

SciBase Holding AB (publ), corporate identity number 556773-4768, is the Parent Company of the Group. The company was formed in 2009 following a restructuring of the Group. The actual operations are conducted by the fully owned subsidiary SciBase AB.

As per June 30, 2018, there were three employees, the CEO and the Groups finance department. The operations consist of consulting activities for the rest of the Group. The company's main task is of a financial nature – to fund the Group's operational activities.

Net sales for the period reached TSEK 2,153 (2,153). The loss for the period amounted to TSEK 22,602 (25,279). The Company's net sales consist of invoiced consultancy fees to the fully owned subsidiary SciBase AB.

The shareholders' contributions to the fully owned subsidiary SciBase AB has from 2016 and onwards been decided to be charged to earnings and not be booked as a financial tangible asset. The shareholders contribution expensed in the period was MSEK 20.4 (23,5).

Significant events during the quarter

In the period major and important improvements to Nevisense was presented. The key improvement is the elimination of the need for a reference measurement, which up until now has been the most complex part of the Nevisense test. Removing this streamlines the measurement procedure and makes Nevisense straightforward to learn and use. This is a very important improvement in usability and makes the product much easier to integrate into the patient flow at dermatology clinics. At the same time the new algorithm has been shown to provide an improved level of clinical accuracy. Sensitivity has remained very high and increased slightly to 97%. Specificity has increased to 38% and negative predictive value (NPV) has improved to 99%. The Nevisense 3.0 upgrade has initially been installed at a core group of 25 users in the EU (primarily Germany) in June, and will be available for general release after the summer.

The AGM 2018 was held on May 16, 2018. The meeting resolved to adopt the profit and loss account and balance sheet for the group and the Company included in the annual report, to adopt the profit and loss distribution, to discharge the board members and managing director from liability, re-election of Tord Lendau, Per Aniansson, Thomas Eklund, Diana Ferro and Thomas Taapken. The meeting also decided upon the board fees and resolved to adopt guidelines for determination of salary and other remuneration to senior management in accordance the Board's proposal. Pricewaterhouse-Coopers AB (PwC) (re-election) was elected as auditor with Magnus Lagerberg as responsible auditor.

Furthermore, the meeting resolved to adopt principles for the appointment the nominating committee for the annual general meeting 2019. The meeting resolved unanimously to authorize the board of directors to, during the time until the next annual general meeting, decide upon issuances of new shares, issuance of warrants and/or convertibles. New issues of shares and issues of warrants and/or convertibles may occur with or without preferential rights for shareholders of the Company and payment may be used for strategic acquisitions, and may be made either in cash and/or by way of set-off or contribution in kind or otherwise on specific terms. The number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall not exceed 1,661,810.

The annual report 2017 was published.

Significant events after the period

The FOBI meeting in Munich in July, which is one of the most important meetings in Germany of the year, was the first meeting where the improved Nevisense was presented. Prof Axel Hauschild also presented Nevisense in a very successful workshop with nearly 100 attendees

Consolidated summary Income Statement

SEK 000'	Apr 1 - June 30 2018	Apr 1 - June 30 2017	Jan 1 - June 30 2018	Jan 1 - June 30 2017	July 1, 2018 - June 30, 2018 Rolling-12	Jan 1 - Dec 31 2017
Net sales	1 571	2 046	3 510	3 801	6 568	6 859
Cost of goods sold	-656	-1 346	-1 696	-2 636	-3 493	-4 433
Gross Profit/Loss	914	700	1 814	1 165	3 074	2 425
Sales and marketing expenses	-5 765	-6 022	-11 714	-11 523	-23 010	-22 820
Administration expenses	-2 502	-2 378	-4 646	-4 848	-8 898	-9 100
Development expenses	-2 903	-3 979	-5 279	-8 046	-10 094	-12 861
Other operating income	93	72	102	88	177	163
Other operating expenses	-76	-111	-106	-165	-181	-240
Operating Income	-10 239	-11 718	-19 829	-23 329	-38 933	-42 433
Financial income	1	7	2	12	19	29
Financial expenses	-60	-35	-127	-41	-146	-60
Profit/Loss before taxes	-10 298	-11 746	-19 955	-23 358	-39 060	-42 464
Income tax	-	-	0	0	0	0
Profit/Loss for the period	-10 298	-11 746	-19 955	-23 358	-39 060	-42 464
Net Profit/Loss attributable to:						
Parent company shareholders	-10 298	-11 746	-19 955	-23 358	-39 060	-42 464
Earnings per share based on Net Profit/loss attributable to parent company shareholders (in SEK/share)						
Profit/loss per share (before and after dilution)*	-0,62	-1,42	-1,20	-2,82	-3,09	-5,00
Average number of shares outstanding	16 618	8 285	16 618	8 285	12 660	8 493

**Profit/loss per share after dilution is not reported, since this would imply improved earnings per share*

Consolidated summary statement of comprehensive income

SEK 000'	Apr 1 - June 30 2018	Apr 1 - June 30 2017	Jan 1 - June 30 2018	Jan 1 - June 30 2017	July 1, 2018 - June 30, 2018 Rolling-12	Jan 1 - Dec 31 2017
Profit/loss for the period	-10 298	-11 746	-19 955	-23 358	-39 060	-42 464
Other comprehensive income for the period:						
Items that have or may be reclassified to profit or loss:						
Changes in fair value on financial assets that can be sold	147	-1	47	-3	42	-8
Tax effect attributable to changes in fair value on financial assets that can be sold	1	1	2	1	3	2
Translation differences on foreign operations	-126	54	-128	57	-455	-270
Sum other comprehensive income	22	54	-79	55	-410	-276
Total comprehensive income for the period	-10 277	-11 692	-20 034	-23 303	-39 471	-42 740
Total comprehensive income attributable to:						
Parent company shareholders	-10 277	-11 692	-20 034	-23 303	-39 471	-42 740

Consolidated summary statement of financial position

	June 30		Dec 31
SEK 000'	2018	2017	2017
ASSETS			
Fixed Assets			
Tangible fixed assets	8 463	8 911	8 761
Financial fixed assets	1 215	1 173	1 168
Total Tangible Assets	9 678	10 084	9 929
Current Assets			
Inventory	4 366	4 113	4 514
Current tax receivable	846	846	548
Receivables	1 414	1 150	1 390
Cash equivalents	85 231	60 974	110 015
Total Current Assets	94 329	69 525	117 983
Total Assets	104 007	79 609	127 912
Shareholders' Equity and Liabilities			
Shareholders' equity attributable to parent company shareholders	95 690	69 402	115 724
Longterm Liabilities			
Deferred tax liability	15	24	23
Total Longterm Liabilities	15	24	23
Current Liabilities			
Accounts payable	1 030	3 431	1 803
Other current liabilities	7 272	6 752	10 362
Total Current Liabilities	8 302	10 183	12 165
Total Liabilites	8 317	10 207	12 188
Total shareolders' equity and liabilities	104 007	79 609	127 912

Consolidated change in shareholders' equity

SEK 000'	Share Capital	Other Capital Contributions	Reserves	Accumulated Loss	Total shareholders' Equity attributable to parent company shareholders
Opening balance Jan 1, 2017	30 654	428 468	156	-366 573	92 705
Profit/loss for the period				-23 358	-23 358
Other comprehensive income			55		55
Total comprehensive income	0	0	55	-23 358	-23 303
Transactions with shareholders:					
Total transactions with shareholders	0	0	0	0	0
Closing balance June 30, 2017	30 654	428 468	211	-389 931	69 402
Opening balance Jan 1, 2018	61 487	463 393	-120	-409 037	115 724
Profit/loss for the period				-19 955	-19 955
Other comprehensive income			-79		-79
Total comprehensive income	0	0	-79	-19 955	-20 034
Transactions with shareholders:					
Total transactions with shareholders	0	0	0	0	0
Closing balance June 30, 2018	61 487	463 393	-199	-428 991	95 690

Consolidated summary statement of cash flows

	Apr 1 - June 30		Jan 1 - June 30		July 1, 2018 - June 30, 2018	Jan 1 - Dec 31
SEK 000'	2018	2017	2018	2017	Rolling-12	2017
Cashflow from operating activities before change in working capital	-9 930	-11 521	-19 276	-22 944	-38 328	-41 996
Cashflows from changes in working capital						
Change in Inventory	424	-861	148	-75	-252	-476
Change in Receivables	1 115	-582	4 120	-814	5 106	171
Change in Liabilities	-1 727	1 920	-4 793	808	-7 480	-1 879
Total change in working capital	*-189*	*477*	*-525*	*-81*	*-2 627*	*-2 183*
Cashflow from operating activities	-10 119	-11 044	-19 801	-23 025	-40 955	-44 180
Investment activities						
Acquisitions of Fixed Assets	-146	-628	-251	-973	-518	-1 240
Cashflow from investment activities	-146	-628	-251	-973	-518	-1 240
Financing activities						
New share issues	-	-	0	-	75 000	75 000
Expenses related to new share issues	0	-	-4 669	-	-9 242	-4 573
Cashflow from financing activities	0	0	-4 669	0	65 758	70 427
Cashflow for the period	-10 265	-11 672	-24 721	-23 998	24 285	25 008
Cash equivalents at start of the year	95 542	72 627	110 015	84 955	60 974	84 955
Exchange rate differences in cash equivalents	-45	19	-63	17	-28	52
Cash equivalents at end of the period	85 232	60 974	85 232	60 974	85 232	110 015

Income statement, Parent Company

SEK 000'	Apr 1 - June 30 2018	Apr 1 - June 30 2017	Jan 1 - June 30 2018	Jan 1 - June 30 2017	July 1 2017 - June 30, 2018 Rolling-12	Jan 1 - Dec 31 2017
Net Sales	1 077	1 076	2 153	2 153	4 306	4 306
Gross profit	1 077	1076	2 153	2153	6 459	4306
Administration expenses	-2 206	-2 065	-4 242	-3 870	-8 346	-7 974
Other expenses	-	-	0	-	-4	-4
Operating Profit/loss	-1 129	-989	-2 088	-1 717	-4 043	-3 672
Earnings from financial items:						
Profit/Loss from shares in group companies	-9 014	-10 617	-20 392	-23 530	-35 121	-38259
Financial income	-	-	-	-	-	-
Financial expenses	-60	-32	-122	-32	-163	-41
Profit/loss after financial items	-10 203	-11 638	-22 602	-25 279	-39 327	-41 972
Taxes	-	-	-	-	-	-
Profit/loss for the period	-10 203	-11 638	-22 602	-25 279	-39 327	-41 972

Statement of other comprehensive income, Parent Company

SEK 000'	Apr 1 - June 30 2018	Apr 1 - June 30 2017	Jan 1 - June 30 2018	Jan 1 - June 30 2017	July 1 2017 - June 30, 2018 Rolling-12	Jan 1 - Dec 31 2017
Profit/loss for the period	-10 203	-11 638	-22 602	-25 279	-39 327	-41 972
Other comprehensive income	-	-	-	-	-	-
Total other comprehensive income	-	-	-	-	-	-
Total comprehensive income	-10 203	-11 638	-22 602	-25 279	-39 327	-41 972

Summary Balance Sheet, Parent Company

	June 30		Dec 31
SEK 000'	2018	2017	2018
ASSETS			
Fixed Assets			
Shares in Group Companies	137 646	137 646	137 646
Total Fixed Assets	137 646	137 646	137 646
Current Assets			
Current receivables and prepaids	29 729	38 921	26 163
Cash equivalents	56 579	19 899	86 973
Total Current Assets	86 307	58 820	113 136
TOTAL ASSETS	223 953	196 466	250 782
SHAREHOLDERS' EQUITY AND LIABILITIES			
Shareholder's equity			
Restricted equity			
Share capital	61 487	30 654	61 487
Non-restricted equity			
Other capital contributions	463 447	428 521	463 447
Retained earnings	-281 254	-239 282	-239 282
Profit/Loss for the period	-22 602	-25 283	-41 972
Shareholders equity	221 078	194 610	243 680
Current liabilities	2 875	1 856	7 102
Total liabilities	2 875	1 856	7 102
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	223 953	196 466	250 782

Notes

Note 1 Accounting principles

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. For the Parent Company, the interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Securities Market Act in accordance with the provisions of RFR 2. For both the Group and the Parent Company the same accounting principles and bases for calculation have been applied as in its most recent Annual Report. Significant accounting and valuation principles are detailed on pages 47-53 of the consolidated annual report for 2017.

New or revised IFRS standards and interpretations by the IFRS Interpretations Committee have not had an effect on the Group's or Parent Company's earnings, financial position or disclosures. The Company has performed a review of IFRS 15 and its impact on the Groups revenue recognition. In the analysis, the Groups contractual- and performance obligations were reviewed. The analysis performed shows that IFRS 15 will not have a material effect on the Groups revenue recognition.

Note 2 Fair value of financial instruments

Current receivables and liabilities

For current receivables and liabilities, such as accounts receivable and accounts payable with a maturity of less than six months, the carrying amount is considered to reflect fair value.

Financial fixed assets

The Groups financial fixed assets, which consist of cash funds, are traded in an active market and fair value is calculated based on the last quoted bid price on the balance sheet date. These assets are included in Level 1 of the fair value hierarchy.

Note 3 Contingent Liabilities

The Parent Company issued a capital adequacy guarantee to its wholly owned subsidiary SciBase AB for a maximum of TSEK 55,000 that is valid until the end of 2018. The corresponding agreement was in-place in 2017, 2016, 2015 and 2014 as well.

Note 4 Seasonal effects

To a certain extent, SciBase's sales and operating profit are expected to be dependent on seasonal variation that the company cannot influence. In the third quarter, due to the vacation period, the number of tests performed is expected to decrease and consequently the company's sales are also expected to dip.

Note 5 Information regarding operating segments

The Group has today only one operating segment, detection of malignant melanoma. Follow-ups are done on the geographical areas, Europe/Rest of the World, US/North America and Asia/Oceania.

Second quarter

Europe/Rest of the World

Net sales during the period amounted to TSEK 1,571 (2,046) of which Germany accounted for 100 (91)%. In the period the focus for the sales and marketing effort has continued to be Germany with the Company's own sales organization. Gross profit amounted to a profit of TSEK 914 (700).

Other geographical areas

Net sales during the period amounted to TSEK 0 (0). Gross profit amounted to TSEK 0 (0).

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

First half-year

Europe/Rest of the World

Net sales during the period amounted to TSEK 3,463 (3,801) of which Germany accounted for 99 (92)%. In the period the focus for the sales and marketing effort has continued to be Germany with the Company's own sales organization. However, a considerable effort has also been made to get other markets to start generating sales. Gross profit amounted to a profit of TSEK 1,790 (1,165).

Other geographical areas

Net sales during the period amounted to TSEK 47 (0). The net sales in the period are related to the second commercial order in the US. Outside the US, it is only in Australia that the company is present, via a distributor. Gross profit amounted to TSEK 24 (0).

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

SEK 000'	Apr 1 - June 30, 2018 Europe/ Rest of the World	Apr 1 - June 30, 2018 Other Segments	Apr 1 - June 30, 2018 Total	Apr 1 - June 30, 2017 Europe/ Rest of the World	Apr 1 - June 30, 2017 Other Segments	Apr 1 - June 30, 2017 Total
Segment - Net sales	1 571	0	1 571	2 046	0	2 046
Sales between segments	-	-	-	-	-	-
Net sales from external customers	1 571	0	1 571	2 046	0	2 046
Cost of goods	-656	0	-656	-1 346	-	-1 346
Gross Profit/Loss	914	0	914	700	0	700
Operating expenses			-11 153			-12 418
Operating profit/Loss			-10 239			-11 718
Financial Income			1			7
Financial Expenses			-60			-35
Group earnings - before tax			-10 298			-11 746

SEK 000'	Jan 1 - June 30, 2018 Europe/ Rest of the World	Jan 1 - June 30, 2018 Other Segments	Jan 1 - June 30, 2018 Total	Jan 1 - June 30, 2017 Europe/ Rest of the World	Jan 1 - June 30, 2017 Other Segments	Jan 1 - June 30, 2017 Total
Segment - Net sales	3 463	47	3 510	3 801	0	3 801
Sales between segments	-	-	-	-	-	-
Net sales from external customers	3 463	47	3 510	3 801	0	3 801
Cost of goods	-1 672	-24	-1 696	-2 636	-	-2 636
Gross Profit/Loss	1 790	24	1 814	1 165	0	1 165
Operating expenses			-21 643			-24 494
Operating profit/Loss			-19 829			-23 329
Financial Income			2			12
Financial Expenses			-127			-41
Group earnings - before tax			-19 955			-23 358

Revenue per category and segment

	Apr 1 - June 30 2018		Apr 1 - June 30 2017		Jan 1 - June 30 2018		Jan 1 - June 30 2017		Rolling-12		Full Year 2017	
Belopp i tkr	Europe/ Rest of the World	Other segments	Europe/ Rest of the World	Other segments	Europe/ Rest of the World	Other segments	Europe/ Rest of the World	Other segments	Europe/ Rest of the World	Other segments	Europe/ Rest of the World	Other segments
Electrodes	1 463	0	1 610	0	2 802	2	2 834	0	4 967	3	5 114	3
Instruments	107	0	436	0	660	46	967	0	1 385	28	1 714	28
Total	1 571	0	2 046	0	3 463	47	3 801	0	6 352	31	6 828	31

Signatures

The Board of Directors and the President provide their assurance that this interim report provides an accurate view of the operations, position and earnings of the Group and the Parent Company, and that it also describes the principal risks and uncertainties faced by the Parent Company and the companies included within the Group.

(SciBase Holding AB)
Stockholm, August 21, 2018

Tord Lendau Chairman of the Board	Per Aniansson Board member	Thomas Eklund Board member
Diana Ferro Board member	Renee Lucander Board member	Thomas Taapken Board member

Simon Grant
CEO

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August 21, 2018.

This interim report has not been subject to review by the Company's auditors.

Contact person:
Michael Colérus, CFO

Quarterly overview

	2018		2017				2016		
THE GROUP	Q2	Q1	Q4	Q3	Q2	Q1	Q4	Q3	Q2
Net sales, SEK ths	1 571	1 939	1 886	1 172	2 046	1 755	1 935	1 580	1 855
Gross margin, %	58,2%	46,4%	31,5%	56,8%	34,2%	26,5%	35,0%	44,6%	30,1%
Equity/Asset ratio, %	92,0%	91,9%	90,5%	86,9%	87,2%	90,7%	90,8%	91,3%	92,7%
Net indebtness, multiple	0,09	0,09	0,11	0,15	0,15	0,10	0,10	0,09	0,08
Cash equivalents, SEK ths	85 231	95 542	110 015	50 948	60 974	72 627	84 955	98 272	108 786
Cashflow from operating activities, SEK ths	-10 119	-9 682	-11 358	-9 796	-11 044	-11 981	-13 032	-10 459	-13 112
Earnings per share (before and after dilution), SEK	-0,62	-0,58	-1,13	-1,06	-1,42	-1,40	-1,77	-1,50	-1,75
Shaeholder's equity per share, SEK	5,76	6,38	12,69	7,31	8,38	9,79	11,19	12,96	14,45
Average number of shares, 000'	16 618	16 618	9 118	8 285	8 285	8 285	8 285	8 285	8 285
Number of shares at closing of period, 000'	16 618	16 618	16 618	8 285	8 285	8 285	8 285	8 285	8 285
Share price at end of period, SEK	6,45	7,45	7,80	18,09	23,13	19,08	19,00	24,91	17,00
Number of sold electrodes, pieces	4 304	4 134	3 936	3 440	5 232	4 096	5 600	3 168	4 016
Average number of employees	20	20	20	21	21	22	23	22	19

Definitions

Financial key ratios

- TSEK: SEK 000'
- Gross margin, %: Gross profit divided by net sales.
- Operating profit: Operating income less operating expenses.
- Operating margin, %: Operating profit divided by income.
- Equity/assets ratio: Equity at the end of the period divided by total assets at the end of the period.
- Debt/equity ratio: Total liabilities in relation to equity.
- Earnings per share for the period before dilution: Profit for the period divided by average number of shares before dilution.
- Earnings per share for the period after dilution: Profit for the period divided by average number of shares after dilution. Earnings per share after dilution is the same as before dilution because potential ordinary shares do not cause to dilution.
- Shareholders' equity per share: Equity divided by average number of shares.
- Dividend per Share: Dividend for the period divided by average number of shares after dilution.
- Number of shares before dilution at the end of the period: Number of shares in issue before dilution at the end of the period.
- Average number of shares before dilution: Average number of shares during the period before dilution.
- Average number of shares after dilution: Average number of shares in issue after dilution is the same as before dilution because potential ordinary shares do not cause to dilution.
- Number of employees (average): Weighted average number of employees in the relevant period.
- IFRS: International Financial Reporting Standards

Industry specific glossary

- CE labeling: A mandatory conformity marking to show that products sold within the European Economic Area (EEA) since 2008 fulfills the requirements of the acquis. CE labeling is also included on products sold outside the EEA but that are produced in the EEA, or intended for sale there.
- Dermatoscopy or Dermoscopy: Examination of skin lesions with a dermatoscope, a strong magnifying glass with a built-in light source.
- Electrical Impedance Spectroscopy (EIS): A measure of the overall impedance occurring in tissue when alternating current is applied at a series of alternating frequencies. This is measured by transmitting an imperceptible alternating current between the bands on the electrode, which is mounted on the tip of the probe and measures the current.
- FDA: The US Food and Drug Administration is the US authority controlling all aspects of the development, manufacture and commercialization of pharmaceutical products and medical devices in the United States.
- Malignant melanoma: The most dangerous form of skin cancer, consisting of cancer in pigment-producing melanocytes.
- Unnecessary excision: The removal of benign skin lesions/birthmarks.
- Nevi: Lesion.
- PMA: Form of approval required for all Class III devices for FDA approval in the USASA

Alternative performance measures (APM)

This section contains a reconciliation of certain alternate performance measures (APM) against the most reconcilable items in the financial statements. The reporting of APMs has limitations as analytical tools, and should not be viewed without context or as compensation for financial measures prepared in accordance with IFRS. APMs are reported to improve investors' evaluation of ongoing operating profit, as a means of predicting future periods, and to simplify a meaningful comparison of results between periods. Management uses these APMs to evaluate, among other things, ongoing operations compared with previous results, for internal planning and forecasting, as well as for calculation of certain performance-related compensation. The APMs reported in this interim report may differ from measures with similar terms used by other companies.

Gross Margin (%)

	H1-2018	H1-2017
Gross Profit	1 814	1 165
Net Sales	3 510	3 801
Gross Margin (%)	51,7%	30,6%

Definition:
Gross Profit / Loss divided with Net Sales.

Cause of use::
The gross margin shows the difference betweend net sales and the cost of goods sold in % of net sales. The gross margin is affected by several factors such as productmix, price trends, exchange rate fluctuation, efficiency in manufactruing processess etc. This is an important measurement as it provides a better understanding of the Company's progress.

Shareholder Equity ratio (%)

	H1-2018	H1-2017
Total Shareholders' Equity	95 690	69 402
Total Assets	104 007	79 609
Shareholders' Equity ratio (%)	92,0%	87,2%

Definition:
Total Shareholders' Equity at the end of the period divided with Total Assets at the end of the year.

Cause of use:
Shareholders equity ratio shows the Group's financial sustainability and the portion that is financed by equity.

Debt ratio (times)

	H1-2018	H1-2017
Total Liabilities	8 317	10 207
Total Sharholders´Equity	95 690	69 402
Debt ratio (times)	0,09	0,15

Definition:
Total debt in relation to Total Shareholders' Equity.

Cause of use:
The debt ratio indicates how much debt the Company is using to finance its assets relative to the value of of shareholders' equity. It is closely connected to the Shareholder's equity ratio.

Earnings per share, after dilution (sek)

	H1-2018	H1-2017
Profit/Loss for the period	-19 955	-23 358
Average nu,ber of shares (thousand)	16 618	8 285
Earnings per share (sek)	-1,20	-2,82

Definition:
Is the portion of a company's profit allocated allocated to each outstanding share of common stock after dilution. The result per share after the dilution is no different than before the dilution due to that potential common stock do not give rise to a dilution effect.

Cause of use:
This shows the value per share.

Shareholders' equity per share (sek)

	H1-2018	H1-2017
Shareholders' Equity	95 690	69 402
Average nu,ber of shares (thousand)	16 618	8 285
Shareholders' equity per share	5,76	8,38

Definition:
Shareholders' equity divided with the average number of shares after dilution

Cause of use:
The shareholders' equity per share provides a measure of the net worth per share and can be set in relation to the actual stock price

Average number of shares (thousand)

	H1-2018	H1-2017
Opening balance - Jan 1	16 618	8 285
Closing balance - March 31	16 618	8 285
Avergae number of shares (thousand)	16 618	8 285

Definition:
The aveage number of issued shares.

Cause of use:
The average number of shares gives a more accurate picture of the result and shareholders' equity due to the fact that the number of shares can change.

Simon Grant
CEO
+46 72 887 43 99
simon.grant@scibase.com

Michael Colérus
CFO
+46 70 341 34 72
michael.colerus@scibase.com

Read more about the company and its operations at our website >> www.scibase.com

Future reporting dates

Interim report, January – September, November 13 2018

Year-end report 2018, February 2019